Skip to main content
Clinical Trials/KCT0009499
KCT0009499
Completed
未知

Clinical trial for Comparative Study on the effect of oral intake of LB-P9 on maintaining hair health(Random Allocation, Double Blindness, Control Comparison)

ISCure Biosciences0 sites80 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
ISCure Biosciences
Enrollment
80
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 24, 2024
Last Updated
last year
Study Type
Interventional Study
Sex
All

Investigators

Sponsor
ISCure Biosciences

Eligibility Criteria

Inclusion Criteria

  • 1\) Men and women aged 18 to 60 with mild or more damaged hair without healthy hair loss disease
  • \- Adult men and women with a gloss score of 1 to 3 according to the visual evaluation classification method, and a total score of hair damage assessed according to exposure to risk factors, less than 18\.
  • 2\) Subjects who will not engage in any special hair products or hair care and manipulation during the study period
  • 3\) Those who have agreed to maintain the same hair shape, color and length during the study period
  • \- Those whose hair length is 8cm or more when measured from the top of the head
  • 4\) A person who voluntarily agrees to participate and signs a written consent form before the start of this human body application test

Exclusion Criteria

  • 1\) Severe acute kidney or heart disease that could affect the results of the trial in the last six months
  • 2\) Patients with hypertension who are not controlled during screening (blood pressure 180/110mmHg or higher; however, those who are stably controlling blood pressure with drug treatment can participate)
  • 3\) Diabetes patients who are not controlled during screening (HbA1c 9% or more)
  • 4\) Patients with uncontrolled hyperthyroidism or hypothyroidism at screening time
  • 5\) In clinical laboratory examination results during screening, creatinine concentration is more than twice the upper limit of the research institute, or patients with chronic renal failure or kidney disease requiring dialysis
  • 6\) At screening, clinical laboratory examination results show that AST or ALT concentrations are more than twice the normal upper limit of the research institute, or drug/alcoholic hepatitis, cirrhosis, fatty liver patients requiring treatment
  • 7\) a person who complains of severe gastrointestinal symptoms
  • 8\) A person with a history of malignant tumors within the past 5 years
  • 9\) a person with a psychiatric condition
  • 10\) A person with an infectious skin disease

Outcomes

Primary Outcomes

Not specified

Similar Trials